Willow vs TMates: Oral GLP-1 with Tracking vs $199 Flat Semaglutide
Quick verdict: Willow prioritizes a structured oral GLP-1 weight management journey with progress tracking and clinician-led follow-up, while TMates focuses on a flat $199/month compounded semaglutide program with 24/7 U.S. doctor access and consistent per-dose pricing.
Explore Willow’s tracked oral GLP-1 program
How Willow vs TMates differ at a glance
The core distinction in this Willow vs TMates comparison is program model. Willow positions an oral GLP-1 program as a structured weight management journey with wellness tracking and follow-up support, available only when a licensed clinician determines it is medically appropriate. TMates offers compounded semaglutide at a flat $199/month rate, the same price at every dose, with 24/7 access to U.S.-based doctors and nationwide licensing in all 50 states.
Price and billing
Willow’s captured starting price is 299 and the reported Price range/details is 299. TMates advertises a flat $199/month price, presented as “$199/month, every dose, no step-up fees.” TMates also lists multi-month price points on its landing page but emphasizes the flat per-month model as its core pricing message.
See TMates $199/month semaglutide plan
Clinical model and access
Willow: licensed telehealth team and follow-up consultations are part of a structured digital workflow and progress tracking tools. Treatment is available only when a licensed clinician determines it is medically appropriate.
TMates: Clinically dosed compounded semaglutide formulated in U.S. facilities with 24/7 access to U.S.-based doctors, licensed coverage in all 50 states, and virtual check-in appointments for ongoing oversight.
Compare Willow’s clinician-led follow-up
Medication type and regulatory notes
Willow references an oral GLP-1 program. The captured evidence notes that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. TMates provides compounded semaglutide and explicitly notes that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
Support tools and program framing
Willow frames its offering as a structured weight management journey that pairs medication with behavioral scaffolding, progress tracking, and follow-up to convert GLP-1 effects into longer term outcomes. TMates frames its offering as a straightforward, personalized, doctor-supervised GLP-1 experience emphasizing easy access, dosing flexibility via compounded semaglutide, and consistent physician availability.
| Criteria | Willow | TMates |
|---|---|---|
| Starting price | 299 | $199/month flat |
| Medication format | Oral GLP-1 program | Compounded semaglutide injections |
| Clinical access | Licensed telehealth team; follow-up consultations | 24/7 U.S. doctor access; virtual check-ins |
| Program emphasis | Progress tracking and structured follow-up | Flat-rate dosing and accessibility |
| Regulatory note | Compounded medications, when offered, are not FDA-approved | Compounded medications are not FDA-approved |
Practical differences that matter
1) Pricing predictability. TMates promotes a flat $199/month cost with no step-up fees as dose escalates. Willow’s captured pricing shows a higher starting point at 299. If per-dose price escalation is a concern, TMates explicitly avoids step-up fees.
2) Care model. Willow emphasizes a structured program with progress tracking tools and follow-up consultations as part of a telehealth-first workflow. TMates emphasizes clinician availability around the clock and virtual check-ins across all 50 states.
3) Medication approach and sourcing. Willow highlights an oral GLP-1 pathway and a behaviorally structured program. TMates offers compounded semaglutide formulated in U.S.-based facilities and notes dosing flexibility compared to branded products, while also stating compounded meds are not FDA-approved.
Review TMates clinical and shipping details
Bottom line and final recommendation
In a Willow vs TMates comparison, choose based on what you need from care. Willow is described as a structured oral GLP-1 weight management journey with progress tracking and follow-up when a licensed clinician approves treatment. TMates is described as a flat-rate, clinician-supervised compounded semaglutide program at $199/month with 24/7 U.S. doctor access and nationwide licensing. Both note that compounded medications are not FDA-approved where applicable.
Choose Willow if you want a telehealth-first program that emphasizes progress tracking and follow-up as part of a structured weight management journey and are seeking oral GLP-1 options when a licensed clinician determines it is medically appropriate.
Choose TMates if you want a predictable flat $199/month compounded semaglutide program with 24/7 access to U.S.-based doctors, same per-dose pricing as doses escalate, and nationwide licensing in all 50 states.